SEC I	Form 4
-------	--------

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

10b5-1(c). See Ir	nstruction 10.			
1. Name and Address of Reporting Person* <u>Charych Deborah H.</u> (Last) (First) (Middle)		rson [*]	2. Issuer Name and Ticker or Trading Symbol Skye Bioscience, Inc. [SKYE]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 10/28/2024	X Director 10% Owner Officer (give title Other (specify below) below)
11250 EL CAM SUITE 100 (Street) SAN DIEGO (City)	fINO REAL CA (State)	92130 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
		Table I Non	Derivative Securities Acquired Disposed of or Bone	ficially Owned

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Month/Day/Year)	2A. Deemed3.Execution Date,Transaif anyCode ((Month/Day/Year)8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D)	Beneficial Ownership
		Code	v	Amount	(A) or (D)	Price	 Transaction(s) (Instr. 3 and 4) 		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative		Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (Right to Buy)	\$5.15	10/28/2024		Α		70,000		(1)	10/27/2034	Common Stock	70,000	\$0	70,000	D	

Explanation of Responses:

1. The stock option vests in equal monthly installments over the one year period beginning October 28, 2024.

Remarks:

/s/Kaitlyn Arsenault, as Attorneyin-Fact 10/30/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.